Enquire Now
Home
About
Company Overview
Leadership
Sustainability
Overview
Health & Safety
Environment
Responsible Workforce
Ethics
Social Commitment
Responsible Procurement
Compliance
Sustainability Reports
Facilities
Quality
Accreditations
CSR
CDMO Services
Products
Overview
API
Intermediates
Caffeine
Xanthine Derivatives
Acid & Allied
R&D
Investor
Overview
Disclosure
Financial Information
Corporate Governance
Shareholders Information
Code and Policies
Downloads
Annual Reports
Resources
Latest News
Events
Career
Why Aarti Pharmalabs
Job Openings
Contact
Disclosure under Regulation 30 of SEBI LODR, 2015
Home
Disclosure under Regulation 30 of SEBI LODR, 2015
Investor Menu
Overview
Disclosure
Financial Information
Corporate Governance
Shareholders Information
Code and Policies
Downloads
Annual Reports
Disclosure / Outcome
Intimation of Board Meeting
Corporate Restructuring
Material and Recent News
Newspaper Advertisement
Disclosures under Regulation 46 of the SEBI (LODR) Regulations, 2015
BSE India
NSE India
SEBI ODR Website
#1105 (no title)
Change in Management
Dividend Record Date
Related Party Transactions
Annual Secretarial Compliance Report
Disclosure to be made by entities identified as Large Corporates
Certificate on Reconciliation of Share Capital Audit
Credit Ratings
Disclosure under Regulation 30 of SEBI LODR 2015
Performance Stock Option Plan
Appointment of Auditor
Certificate pursuant to Regulation 40(9) of the SEBI (LODR) Regulations, 2015
Compliance Certificate pursuant to Regulation 7(3) of SEBI (LODR) Regulations, 2015
Certificates under SEBI (Depositories and Participants) Regulations, 2018
Sort
Latest
Oldest
Year
2026
2025
2024
Intimation of Plant Closure
May 31, 2024
Clarification on Plant Closure
July 10, 2024
Intimation for signing of Shareholder’s
December 17, 2024
Closure of Manufacturing Activities at the Company's Vapi Plant
January 03, 2025
Acquisition
January 09, 2025
Intimation of Plant Re-opening
January 18, 2025
Acquisition through Power Purchase Agreement
January 09, 2025
Joint Venture through Addendum to Shareholder & Subscription Agreement
April 01, 2025
Patent Violation - Ruxolitinib-JM
October 08, 2025
Appointment of SMP
November 09, 2025
Change in Management
January 01, 2026
Intimation under Reg 30 of SEBI (LODR), 2015
February 06, 2026
Intimation of Chemical Leak
March 24, 2026
Intimation of USFDA observations
March 27, 2026
Investor Menu
May 31, 2024